Core Viewpoint - Weikang Pharmaceutical (300878) is expected to report a net loss attributable to shareholders of between 170 million to 245 million yuan for 2025, compared to a loss of 147 million yuan in the same period last year [2] Group 1: Financial Performance - The company's capacity utilization rate is low, leading to a provision for fixed asset impairment of 45.55 million yuan [2] - The decline in product sales prices and lower-than-expected sales volume have resulted in a decrease in both operating revenue and gross margin [2] - The company has also made a provision for inventory impairment of 30.39 million yuan due to some inventory nearing expiration [2] Group 2: Regulatory Developments - The company has recently received a drug registration certificate from the National Medical Products Administration for its product, Er Dong Tang Granules, which is used for lung and stomach relief [2]
维康药业：2025年预亏1.7亿元~2.45亿元